Radiotherapy and combined modality approaches in localised prostate cancer

European Journal of Cancer

Volumn 37, Issue SUPPL. 7, 2001, Pages

  Dearnaley, David P ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

COMPUTER ASSISTED RADIOTHERAPY; HUMAN; MALE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PHASE 3 CLINICAL TRIAL; PROSTATE TUMOR; REVIEW;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL;

EID: 0035496360     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(01)80015-0     Document Type: Article

References (64)

1. Dearnaley DP, Melia J. Early prostate cancer - to treat or not to treat? Lancet 1997, 349(9056): 892-893.
2. Lu Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer [see comments]. Lancet 1997, 349(9056): 906-910.
3. Consensus conference. The management of clinically localized prostate cancer. JAMA 1987, 20(258): 2727-2730.
4. COIN Guidelines. Guidelines on the Management of Prostate Cancer. Clin Oncol 1999, 11: S55-S88.
5. D'Amico AV, Whittington R, Kaplan I et al. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of >4-20 ng/ml. Int J Radiat Oncol Biol Phys 1997, 37: 1053-1058.
6. Lowe BA, Listrom MB. Incidental carcinoma of the prostate: an analysis of the predictors of progression. J Urol 1988, 140: 1340-1344.
7. Chodak GW, Thisted RA, Gerber GS et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994, 330: 242-248.
8. Perez C, William R, Ihde D. Carcinoma of the prostate. In: VT DeVita, S Hellman, SA Rosenberg (Eds.), Cancer: Principle and Practice of Oncology. 3rd ed. Philadelphia, J.B. Lippincott Company, 1989, pp. 1023-1058 (vol. 1).
9. Shipley W, Thames H, Sandler H et al. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis. JAMA 1999, 281: 1598-1604.
10. Kattan M, Zelefsky M, Kupelian P, Scardino P, Fuks Z, Leibel S. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000, 18: 3352-3359.
11. Crook J, Robertson S, Collin G, Zaleski V, Esche B. Clinical relevance of trans-rectal ultrasound, biopsy and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1993, 27: 31-37.
12. Scardino PT, Bretas F. Interstitial radiotherapy. In: Bruce AW, Trachtenberg J (Eds.), Adenocarcinoma of the Prostate. Springer-Verlag, London, 1987, pp. 145-158.
13. Freiha FS, Bagshaw MA. Carcinoma of the prostate: Results of post-irradiation biopsy. Prostate 1984, 5: 19-25.
14. Hanks GE, Hanlon AL, Hudes G, Lee WR, Suasin W, Schultheiss TE. Patterns-of-failure analysis of patients with high pretreatment prostate-specific antigen levels treated by radiation therapy: the need for improved systemic and locoregional treatment. J Clin Oncol 1996, 14: 1093-1097.
15. Zelefsky M, Leibel S, Gaudin P et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998, 41: 491-500.
16. Hanks GE, Hanlon AL, Schultheiss TE. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimisation, and future directions. Int J Radiat Oncol Biol Phys 1998, 41: 501-510.
17. Hanks GE, Lee WR, Hanlon AL et al. Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > or = 10 ng/ml [see comments]. Int J Radiat Oncol Biol Phys 1996, 35: 861-868.
18. Vicini F, Kestin L, Martinez A. The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. Cancer 2000, 88: 2305-2318.
19. Hanlon A, Hanks G. Failure pattern implications following external beam irradiation of prostate cancer: long-term follow-up and indications of cure. Cancer J Sci Am 2000 (Suppl 2): S193-197.
20. Duncan W, Warde P, Catton CN. Carcinoma of the prostate: results of radical radiotherapy (1970-1985). Int J Radiat Oncol Biol Phys 1993, 26: 203-210.
21. Amdur RJ, Parsons JT, Fitzgerald LT, Million RR. Adenocarcinoma of the prostate treated with external-beam radiation therapy: 5-year minimum follow-up. Radiother Oncol 1990, 18: 235-246.
22. Mithal N, Hoskin P. External beam radiotherapy for carcinoma of the prostate: A retrospective study. Clin Oncology 1990, 18: 297-301.
23. Sagerman RH, Chun HC, King GA, Chung CT, Dalal PS. External beam radiotherapy for carcinoma of the prostate. Cancer 1989, 63: 2468-2474.
24. Zagars GK, von Eschenback AC, Johnson DE, Oswald MJ. Stage C adenocarcinoma of the prostate: An analysis of 551 patients treated with external beam radiation. Cancer 1987, 60: 1489-1499.
25. Aristizabal SA, Steinbronn D, Heusinkveld RS. External beam radiotherapy in cancer of the prostate. Radiother Oncol 1984, 1: 309-315.
26. Forman JD, Zinreich E, Lee Ding-Jen, Wharam MD, Baumgardner RA, Order SE. Improving the therapeutic ratio of external beam irradiation for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1985, 11: 2073-2080.
27. Leibel SA, Hanks GE, Kramer S. Patterns of care outcome studies: Results of the national practice in adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1984, 10: 401-409.
28. Hanks GE, Diamond JJ, Krall JM, Martz KL, Kramer S. A ten year follow-up of 682 patients treated for prostate cancer with radiation therapy in the United States. Int J Radiat Oncol Biol Phys 1987, 13: 499-505.
29. Hanks GE, Krail JM, Martz KL, Diamond JJ, Kramer S. The outcome of treatment of 313 patients with T-1 (UICC) prostate cancer treated with external beam irradiation. Int J Radiat Oncol Biol Phys 1988, 14: 243-248.
30. De Wit L, Ang KK, van der Schueren E. Acute side effects and late complications after radiotherapy of localized carcinoma of the prostate. Cancer Treat Rev 1983, 10: 79-89.
31. Pilepich MV, Krall JM, al Sarraf M et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995, 45: 616-623.
32. Roach MI, Chinn DM, Holland J, Clarke M. A pilot survey of sexual function and quality of life following 3D conformal radiotherapy for clinically localised prostate cancer. Int J Radiat Oncol Biol Phys 1996, 35: 869-874.
33. Potosky A, Legler J, Albertsen P et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000, 92: 1582-1592.
34. Litwin M, Hays R, Fink A et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995, 273: 129-135.
35. Beard CJ, Propert KJ, Rieker PP et al. Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: a prospective multiinstitutional outcomes study. J Clin Oncol 1997, 15: 223-229.
36. Widmark A, Fransson P, Tavelin B. Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer 1994, 74: 2520-2532.
37. Hanks GE, Martz KL, Diamond JJ. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 1988, 15: 1299-1305.
38. Dearnaley DP, Khoo VS, Norman A et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999, 353: 267-272.
39. Sandler HM, Perez-Tamayo C, Ten Haken RK, Lichter AS. Dose escalation for stage C(T3) prostate cancer: minimal rectal toxicity observed using conformal therapy. Radiother Oncol 1992, 23: 53-54.
40. Fiveash J, Hanks GMR et al. 3D conformal radiation therapy (3DCRT) for the high grade prostate cancer: a multi-institutional review. Int J Radiat Oncol Biol Phys 2000, 47: 335-342.
41. Valicenti R, Lu J, Pilepich M, Asbell S, Grignon D. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group Trials. J Clin Oncol 2000, 18: 2740-2746.
42. Pollack A, Zaggars G, Smith L et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000, 18: 3904-3911.
43. Seddon B, Bidmead M, Wilson J, Khoo V, Dearnaley D. Target volume definition in conformal radiotherapy for prostate cancer: quality assurance in the MRC RT-O1 trial. Radiother Oncol 2000, 56: 73-83.
44. Zelefsky M, Cowen D, Fuks Z et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localised prostate carcinoma. Cancer 1999, 85: 2460-2468.
45. Zelefsky M, Fuks Z, Happersett L et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000, 55: 241-249.
46. Zietman AL, Prince EA, Nakfoor BM, Park JJ. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumour system. Int J Radiat Oncol Biol Phys 1997, 38: 1067-1070.
47. Joon DL, Hasegawa M, Sikes C et al. Supra-additive apoptotic response of R3327-G rat prostate tumours to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 1997, 38: 1071-1077.
48. Dearnaley D. Combined modality treatment with radiotherapy and hormonal treatment in localised prostate cancer. In: A Belldegrun, RS Kirby, DWW Newling (Eds.), New Perspective in Prostate Cancer, 2nd ed. Isis Medical Media, 2000, pp. 169-180.
49. Forman JD, Kumar R, Haas G, Montie J, Porter AT, Mesina CF. Neoadjuvant hormonal downsizing of localised carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer Invest 1995, 13: 8-15.
50. Zelefsky MJ, Leibel SA, Burman CM et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1994, 29: 755-761.
51. Pilepich MV, Sause WT, Shipley WU et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomised comparative trial of the radiation therapy Oncology Group. Urology 1995, 45: 616-623.
52. Pilepich MV, Winter K, Roach M et al. Phase III Radiat Oncol Group (RTOG) 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Proc Am Soc Clin Oncol 1998, 17(Abstract 1185): 308a.
53. Porter A, Ethliali M, Manji Mea. A phase III randomised trial to evalute the efficacy of neoadjuvant therapy prior to curative radiotherapy in locally advanced prostate cancer patients. A Canadian Urologie Oncology Group study. Proc Am Soc Clin Oncol 1998, 17: 315a (Abstract 1123).
54. Laverdiere J, Gomez JL, Cusan L et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997, 37(2): 247-252.
55. Pilepich MV, Caplan R, Byhardt RW et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group protocol 85-31. J Clin Oncol 1997, 15: 1013-1021.
56. Lawton C, Winter K, Murray K et al. Updated results of the Phase III Radiation Therapy Oncology Group (RTOG) Trial 85-31. Evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001, 49: 937-946.
57. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [see comments]. N Engl J Med 1997, 337(5): 295-300.
58. Granfors T, Modig H, Damber JE, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998, 159: 2030-2034.
59. Fellows GJ, Clark PB, Beynon LL et al. Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment. A Medical Research Council Study. Br J Urol 1992, 70: 304-309.
60. Dearnaley DP, Horwich A, Shearer RJ. Treatment of advanced localised prostatic cancer by orchidectomy, radiotherapy or combined treatment. A Medical Research Council Study. Br J Urol 1992, 72: 673-674.
61. Hanks G, Lu J, Machtay M et al. RTOG Protocol 92-02: A Phase III Trial of the Use of Long Term Androgen Suppression Following Neoadjuvant Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate. Proc Am Soc Clin Oncol 3 2000, 327a (Abstract 1284).
62. Horwitz E, Winter K, Hanks G, Lawton C, Russell A, Machtay M. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 2001, 49: 947-956.
63. Roach III M, Lu J, Pilepich M et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on radiation therapy oncology group clinical trials. Int J Radiat Oncol Biol Phys 2000, 47: 609-615.
64. Roach III M, Lu J, Pilepich M et al. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 2000, 47: 617-627.